Joana Carvalho, PhD, managing science editor —

The bionic pancreas (BP), an automated system that controls blood sugar levels, may be useful in managing cystic fibrosis-related diabetes, a small study says. The study, “Automated glycemic control with the bionic pancreas in cystic fibrosis-related diabetes: A pilot study,” was published in the Journal of…

Boehringer Ingelheim announced the enrollment of a first patient in its Phase 2 BALANCE-CF 1 trial assessing the safety and efficacy of BI-1265162 to treat cystic fibrosis (CF) regardless of a person’s disease-causing mutations. BI-1265162 is an epithelial sodium channel (ENaC) inhibitor that works to prevent cells lining…

Scientists have discovered a new way to treat cystic fibrosis (CF) that involves delivering artificial proteins to patients’ lung cells to replace the faulty cystic fibrosis transmembrane conductance regulator (CFTR) protein. The finding was reported in the study, “Anion carriers as potential treatments for cystic fibrosis: transport in…

Kristen Mudrack, PhD, a chemistry professor at Milligan College in Tennessee, has launched a research initiative to encourage college students to produce and test antibiotics that target and destroy Pseudomonas aeruginosa, a bacteria highly resistant to antibiotics that often causes lung infections in patients with…

The Cystic Fibrosis Foundation (CFF) is giving Eloxx Pharmaceuticals up to $1.61 million to support its planned Phase 2 clinical trial program assessing the safety, tolerability, and chemical properties of ELX-02, Eloxx’s lead investigational compound to treat cystic fibrosis (CF) caused by nonsense, or stop, mutations. The program…

The lung clearance index (LCI) is more sensitive to changes in lung function in patients with mild cystic fibrosis (CF) than conventional spirometry parameters, a study asserts. The findings were reported in the study, “Lung clearance index to detect the efficacy of Aztreonam lysine inhalation in…

The clinical effectiveness and cost-benefit of several cystic fibrosis (CF) therapies will be the focus of a final evidence report by the Institute for Clinical and Economic Review (ICER), which is currently seeking feedback from CF stakeholders for the report. The report will mainly evaluate the effects of…

A defect in cellular metabolism is the root cause for the high incidence of lung infections caused by the bacteria Pseudomonas aeruginosa in patients with cystic fibrosis (CF), a study has found. Results from the study, “CFTR-PTEN–dependent mitochondrial metabolic dysfunction promotes Pseudomonas aeruginosa airway infection,” were published in…

The Scottish Medicines Consortium (SMC) is recommending against bringing two of Vertex Pharmaceuticals’ approved cystic fibrosis (CF) treatments — Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor) — into routine use by adding them to the country’s national health system. Each treatment’s “cost in relation to its health…

Italfarmaco SpA entered an agreement with Neupharma to develop and commercialize an inhaled formulation of teicoplanin, one of the most effective antibiotics to treat lung infections caused by resistant strains of Staphylococcus aureus in people with cystic fibrosis (CF). Under the terms of the agreement, Italfarmaco shall hold…